english.prescrire.org > Spotlight > "Spotlight"
"Spotlight"

Prescrire's yearly review of new drugs and indications in 2014

In its annual recap of drugs reviewed over the past year, independent French medical journal Prescrire points to some advances, but many drugs are poorly evaluated, too expensive or more dangerous than useful.

Summary

  • Three drugs analysed by Prescrire in 2014 provided a significant therapeutic advance for some patients.
     
  • In 2014, too many drugs are still best avoided, have undergone minimal evaluation, or are excessively expensive.

  • Drug regulatory agencies should continue their efforts to improve pharmacovigilance and transparency.

©Prescrire 1 April 2015

"New drugs and indications in 2014" Prescrire Int 2015; 24 (159): 107-110. (Pdf, free)